NCT02733627View on ClinicalTrials.gov

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

July 12, 2017

Study Completion Date

July 12, 2017

Conditions
Healthy
Interventions
DRUG

BI 1467335

DRUG

Placebo

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY